

An efficient scoring model for diagnosis of tuberculous pleural effusion

Senquan Wu (✉ 873508640@qq.com)

Dongguan People's Hospital

Shaomei Li

Dongguan People's Hospital

Nianxin Fang

Dongguan People's Hospital

Weiliang Mo

Dongguan People's Hospital

Huadong Wang

Jinan University

Ping Zhang

Dongguan People's Hospital

Research Article

Keywords: Tuberculosis, Pleural effusion, Tuberculous pleural effusion, Scoring model

Posted Date: October 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-957673/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

An efficient scoring model for diagnosis of tuberculous pleural effusion

Senquan Wu^{1,2*#}, Shaomei Li^{1#}, Nianxin Fang^{1#}, Weiliang Mo¹, Huadong Wang^{2*} and Ping Zhang^{1*}

¹*Department of Respiratory and Critical Care Medicine, Dongguan People's Hospital, Dongguan, Guangdong, China;* ²*Department of Pathophysiology, Key Laboratory of State Administration of Traditional Chinese Medicine of the People's Republic of China, School of Medicine, Jinan University, Guangzhou, Guangdong, China.*

*Corresponding author: Senquan Wu, 873508640@qq.com, Dongguan People's Hospital, 3 Wanda Road South, Dongguan 523059, Guangdong, China; Huadong Wang, owanghd@jnu.edu.cn, Department of Pathophysiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China; Ping Zhang, 1728340667@qq.com, Dongguan People's Hospital, 3 Wanda Road South, Dongguan 523059, Guangdong China.

These authors have contributed equally to this work.

1 **An efficient scoring model for diagnosis of tuberculous pleural
2 effusion**

3

4 **ABSTRACT**

5 **Background:** Due to the low efficiency of single clinical feature or laboratory variable
6 in the diagnosis of tuberculous pleural effusion (TBPE), The diagnosis of TBPE is still
7 challenging. This study aimed to build an efficient scoring diagnostic model based on
8 laboratory variables and clinical features to differentiate TBPE from non-tuberculous
9 pleural effusion(non-TBPE).

10 **Methods:** A retrospective study of 125 patients (63 with TBPE; 62 with non-TBPE)
11 were undertaken. Univariate analysis was used to select the laboratory and clinical
12 variables relevant to the model composition. The statistically different variables were
13 selected to undergo binary logistic regression. Variables B coefficients were used to
14 define a numerical score to calculate a scoring model. A receiver operating
15 characteristic (ROC) curve was used to calculate the best cut-off value and evaluate the
16 performance of the model.

17 **Results:** Six variables were selected in the scoring model: Age \leq 46 years old (4.96
18 point), Male (2.44 point), No cancer (3.19 point), Positive T-cell Spot (T-SPOT) results
19 (4.69 point), Adenosine Deaminase (ADA) \geq 24.5U/L (2.48 point), C-reactive Protein
20 (CRP) \geq 52.8mg/L (1.84 point). With a cut-off value of total score was 11.038 points,
21 the sensitivity, specificity and accuracy of the scoring model was 93.7%, 96.8% and
22 99.2% respectively.

23 **Conclusion:** The scoring model was efficient to differentiate TBPE from non-TBPE.

24 **KEYWORDS:** Tuberculosis; Pleural effusion; Tuberculous pleural effusion; Scoring
25 model

26

27 **Introduction**

28 Tuberculosis (TB) affects about nine million people and 1.5 million deaths worldwide
29 every year [1]. In 2016, tuberculosis claimed 1.3 million lives among HIV-negative
30 people, exceeding the total number of deaths caused by HIV and becoming
31 the first killer among infectious diseases [2]. On Sep 26, 2018, all UN Member States
32 promised to end the global tuberculosis epidemic by 2030 in the UN General Assembly
33 High Level meeting [3]. Currently, pleural tuberculosis (PT) has been a most common
34 type of extrapulmonary tuberculosis, and its frequency of all TB varies greatly in
35 different countries. PT accounts for more than 20% of all TB cases in Africa [4, 5], 6.5
36 to 8.7% in China [6, 7], 8.7% in Brazil [8], and 3.7% in the United States [9]. PT appears
37 to be the main cause of pleural effusion (PE) in countries with a high prevalence of
38 tuberculosis (e.g. in India) [10].

39 Tuberculous pleural effusion (TBPE) accounts for about 40% of PE cases in China
40 [11, 12]. For patients with TBPE, untimely anti-tuberculosis treatment will affect its
41 prognosis. The diagnostic criteria of TBPE is dependent on bacteria culture and
42 histopathology, but the diagnostic sensitivity is limited and time consuming.
43 Thoracoscopic Pleural Biopsy is an effective method in the diagnosis of TBPE, but its
44 application is limited because of its invasiveness, complexity and technical difficulty

45 [5, 13, 14]. Moreover, the diagnostic value of single clinical biomarker of TBPE is
46 limited, including erythrocyte sedimentation rate (ESR), blood T-cell spot (T-SPOT),
47 adenosine deaminase (ADA) and lymphocyte ratio, so the diagnosis of TBPE is still
48 challenging. Thus, our study aimed to build an efficient scoring diagnostic model based
49 on laboratory variables and clinical features to differentiate TBPE from non-TBPE.

50

51 **Methods**

52 ***Study subjects***

53 A retrospective study was conducted in the period 2016–2021 after approval by the
54 Ethics Committee of Dongguan People's Hospital. All the enrolled patients met the
55 indications of thoracic puncture or thoracoscopic pleural biopsy and signed the
56 informed contents. The patients selected in the study should meet the following criteria:
57 (1) Adult group; (2) Presence of PE on chest radiographs and ultrasonography; (3)
58 Complete data in clinical were available for all patients. Finally, a total of 125 PE
59 patients were included in this study.

60

61 ***Diagnostic Criteria***

62 TBPE diagnosis was confirmed when PE met at least one of the following criteria: (1)
63 pleural fluid/sputum/bronchial aspirate/bronchoscopic brushing specimen
64 were positive for acid-fast bacilli or positive culture or positive polymerase chain
65 reaction (PCR) for *Mycobacterium tuberculosis*. (2) Positive acid-fast staining or
66 epithelioid caseous granuloma in pleural or lung tissue [15-17].

67 Malignant Pleural Effusion (MPE) was diagnosed when pleural histopathology
68 demonstrated malignant lesions or when when cytological
69 examination of pleural effusion demonstrated malignant cells.

70 Empyema cases with negative M. tuberculosis culture were confirmed according to
71 ATS guidelines [18]. Parapneumonic effusion (PPE) was caused by pneumonia which
72 was confirmed based on the criteria of the American Thoracic Society (ATS) [19].
73 Thoracoscopic pleural biopsy was performed in patients with unknown etiology of PE.
74 Except for the cases with TBPE, all the other cases were classified as non-TBPE group.

75 All patients underwent a standard thoracocentesis procedure to
76 collect pleural effusion samples and blood was collected by venupuncture before
77 intervention procedures. Record items include: sex, age, clinical symptoms (cough,
78 fever, chest pain, night sweats), T-SPOT, ESR, C-reactive protein (CRP), PE
79 lymphocyte ratio, PE protein, PE lactate dehydrogenase (LDH), ADA, PE location,
80 presence of cancer or not. Patients who had incomplete data were excluded in this
81 study. the statistical analysis was performed using the data from the first pleural fluid
82 sample before treatment. Hematological data were collected from the blood samples
83 taken nearest to the first thoracentesis.

84 T-SPOT TB test was measured using Enzyme-Linked Immunospot (T-SPOT TB
85 assay kit, Oxford Immunotec Co., Ltd., Abingdon, UK). Pleural effusion protein was
86 measured using Colorimetric Determination (Dry tablets assay kit, Ortho-Clinical
87 Diagnostics Co., Ltd., New York, USA). The activity of ADA was measured using
88 peroxidase assay (ADA assay kit, Beijing Leadman Biochemistry Co., Ltd., Beijing,

89 China). LDH levels were measured using the lactic acid substrate method (LDH assay
90 kit, Beckman Coulter Laboratory Systems Co., Ltd., Suzhou, China). CRP level was
91 measured using Quantitative Immunofluorescence method (Boditech Biotechnology
92 Co., Ltd., Guangxi, China). ESR was measured using an Italian
93 Microsed-System Automatic Blood Sedimentation Instrument. Differential cell counts
94 in PE were counted manually.

95

96 ***Statistical analysis***

97 The analyses were carried out using SPSS 22.0 software (SPSS Inc., Chicago, IL, USA).
98 Continuous data are reported as median, with first and third quartiles. Mann–Whitney
99 U test was used for comparisons between groups. Chi-square test was used for the
100 analysis of categorical variables. The results with p values less than 0.05 were
101 considered as statistical significance. Sensitivity, specificity, positive predictive value
102 (PPV), negative predictive value (NPV), accuracy and Youden index were calculated
103 to estimate the diagnostic performance of the indicators. In addition, receiver operating
104 characteristic (ROC) curve was plotted to evaluate the diagnostic value of continuous
105 data for TBPE, and the continuous variable was converted into a binary variable
106 according to the cut-off value corresponding to the maximum value of the
107 Youden Index. The factors with statistically significant differences between the two
108 groups were selected in the binary logistic regression. A goodness-of-fit test of the
109 binary logistic regression model was evaluated by Hosmer and Lemeshow test.
110 Variables B coefficients were used to define a numerical score to calculate a scoring

111 model. A receiver operating characteristic (ROC) curve was used to calculate the best
112 cut-off value and evaluate the performance of the scoring model.

113

114 **Results**

115 ***Clinical and laboratory findings of the 125 patients with PE***

116 In this study, a total of 125 patients (63 with TBPE; 62 with non-TBPE) were enrolled
117 according to the selection criteria. The demographic and clinical characteristics were
118 collected from the patient's medical records and summarized in **Table 1**. It was no
119 significant difference between two groups in cough, chest pain, night sweats, pleural
120 fluid protein and LDH ($p > 0.05$), But there were significant differences among age,
121 male, cancer diagnosis, pleural fluid location, fever, ESR, CRP, T-SPOT, pleural fluid
122 lymphocyte ratio and ADA ($p < 0.05$). The mean age of TBPE group was lower than
123 that of non-TBPE group. TBPE predominated in men (46/63, 73.0%) who with
124 unilateral pleural effusion (62/63, 98.4%). MPE accounts for most of the non-TBPE
125 (43/62, 69.4%). The proportion of fever, positive T-SPOT and the mean values of ESR,
126 CRP, pleural fluid lymphocyte ratio, ADA in patients with TBPE was higher than that
127 of patients with non-TBPE.

128

129 ***The diagnostic performance of single indicator for TBPE***

130 ROC curve was used to evaluate the diagnostic value of continuous data (**Figure**
131 **1A and 1B**), and the continuous variable was converted into a binary variable according
132 to the cut-off value corresponding to the maximum value of the Youden Index (**Table**

133 2). The diagnostic performance, including Sensitivity, Specificity, Positive predictive
134 value (PPV), Negative predictive value (NPV) and Accuracy, were calculated and
135 summarized in **Table 3**.

136

137 ***The multivariate logistic regression of binary variables and the establishment of the***
138 ***scoring model***

139 The factors with statistically significant differences between two groups were
140 selected in the logistic regression, using forward selection method to select indicators
141 to enter the final model. At last, ESR \geq 27.5 mm/h, fever, lymphocyte ratio \geq 91.5%,
142 unilateral pleural effusion was eliminated by the model, And age \leq 46.5 years, male, no
143 cancer, positive T-SPOT, CRP \geq 52.8 mg/L, ADA \geq 24.5 U/L were accepted into the final
144 binary logistic regression model. Hosmer and Lemeshow test Confirmed a good
145 goodness-of-fit test of the binary logistic regression model($P=0.499$). Variables B
146 coefficients were used to define a numerical score to calculate a scoring model (table4).

147

148 ***The diagnostic performance of scoring model***

149 The total score is equal to the sum of the score of the Variables in **Table 4** when
150 matching the scoring criteria. The calculation equation as follow: Y (total score) =Age
151 score +Gender score +Cancer score +T-SPOT score +CRP score +ADA score. ROC
152 curve was used to calculate the best cut-off value. When total score \geq 11.038, The area
153 under the curve (AUC) value was 0.992 (95%CI: 0.982–1.000) (**figure 2**). The
154 performance of the total scoring model for diagnosis TBPE were Summarized in **table**

155 5.

156

157 **Discussion**

158 There are many causes of pleural effusion. Since the high prevalence of TB was
159 occurred in China, TBPE accounts for about 40% of pleural effusion [11, 12]. Currently,
160 the diagnostic performance of clinical feature or laboratory variable in diagnosing
161 TBPE was poor, therefore it's urgent need to find a new method to diagnose TBPE. Our
162 study had built an efficient scoring diagnostic model by using logistic regression based
163 on laboratory variables and clinical features to differentiate TBPE from non-TBPE.

164 A total of 15 indicators were included in this study. There were no any symptoms
165 were introduced into the final binary logistic regression model, which shows that
166 clinical symptoms had no significant diagnosis value to the TBPE. And the results was
167 similar to the previously reported data [20]. In terms of pleural effusion tests, unilateral
168 pleural effusion, pleural effusion protein, LDH, and pleural effusion lymphocytes ratio
169 ultimately failed to enter the final model, and it may due to TBPE and MPE are
170 dominated by unilateral lymphocytic exudates [21], and most of the PE in this study
171 were MPE. ESR, a non-specific indicator for the diagnosis of TBPE, as expected, was
172 eventually eliminated by the regression model, even though there was difference in
173 univariate analysis between two groups.

174 Finally, six indicators of age, sex, cancer, CRP, T-SPOT and ADA were included
175 in the diagnostic scoring model by multivariate binary logistics regression, which
176 showed that those six indicators made a great contribution to the diagnosis. In terms of

177 age, the non-TBPE group was significantly older than the TBPE group, which may
178 attribute to the elderly-onset of cancer that was the main causes of non-TBPE. Our
179 result showed that TBPE predominated in men (46/63; 73.0%), while MPE
180 predominated in females (37/62; 59.6%), and it was similar to the previously reported
181 data of Roberta et al [21]. Consistent with the previously studies [22], we also
182 demonstrated the potential diagnostic value of CRP for TBPE. The
183 sensitivity and specificity of ADA, had a good diagnostic performance in diagnosis of
184 TBPE, were above 90% in diagnosing TBPE, and T-SPOT also showed a good
185 diagnostic value for the diagnosis of TBPE that the sensitivity and specificity were 93.7%
186 and 77.4% respectively. Above results were similar to the previous studies [20, 23, 24].

187 Hosmer and Lemeshow test confirmed a good goodness-of-fit test of the binary
188 logistic regression model ($p = 0.499$). The performance of the scoring model for
189 diagnosis TBPE were evaluated by ROC curve, when total score ≥ 11.038 , the AUC
190 value was 0.992 (95%CI: 0.982–1.000), the sensitivity, specificity, PPV, NPV were
191 93.7%, 96.8%, 100% and 93.9% respectively, the diagnostic performance of the scoring
192 model was better than the reported data of Petborom et al [20, 25]. Our scoring model
193 can aid to diagnosis TBPE and provide more evidence for anti-tuberculosis treatment,
194 but we need to track the effect of treatment to verify the accuracy of the diagnostic
195 model follow-up. When anti-tuberculosis treatment is ineffective, a thoracoscopic
196 pleural biopsy should be used to further confirm the diagnosis. For medical units with
197 limited sanitary conditions, the diagnostic model can help to find TBPE, so that patients
198 can be referred to specialist hospitals for earlier treatment.

199 The retrospective study has the selection bias, for example, patients with
200 incomplete data were excluded from the study which leading to a reduction in the
201 number of cases. Some test indicators, such as cytokines, CD4 and CD8 were not
202 included in our study because of the small number of people tested. Therefore, the
203 establishment of a better TBPE diagnostic scoring model requires a prospective study,
204 multi-center study to achieve.

205

206 **Conclusions**

207 The diagnostic score model established by logistic regression combined with multiple
208 indicators improves diagnostic performance. It is significantly higher than a single
209 index of laboratory variables or clinical features in diagnosing TBPE. In brief,
210 establishing a scoring model for the diagnosis of TBPE provide a more economical,
211 effective, and faster diagnostic method based on routine clinical data to assist clinicians
212 in making better clinical decisions.

213

214 **Abbreviations**

215 TB: Tuberculosis; TBPE: Tuberculous Pleural Effusion; ROC: Receiver Operating
216 Characteristic; T-SPOT: T-cell Spot; ADA: Adenosine Deaminase; CRP: C-reactive Protein;
217 PT: Pleural Tuberculosis; PE: pleural effusion; ESR: Erythrocyte Sedimentation Rate; LDH:
218 Lactate Dehydrogenase; PPV: Positive Predictive Value; NPV: Negative Predictive Value.

219

220 **Acknowledgements**

221 Not applicable.

222

223 **Authors' contributions**

224 All listed authors meet the requirements for authorship. SW, HW and PZ conceived
225 and designed the study. SL, NF and WM collected clinical information. SW, SL and
226 NF analyzed the data. SW wrote the manuscript. All authors critically reviewed and
227 approved the final manuscript.

228

229 **Funding**

230 This work was supported by grants from the Dongguan Social Science and Technology
231 Development Project [No 202050715001774].

232

233 **Availability of data and materials**

234 Most of the data was included in the submission. The more details of the data were
235 available from the corresponding authors on reasonable request.

236

237 **Declarations**

238

239 **Ethics approval and consent to participate**

240 This study was approved by the Ethics Committee of Dongguan People's Hospital, and
241 the institutional review board approved a waiver of patient informed consent.

242 **Consent for publication**

243 Not applicable.

244

245 **Competing interests**

246 No potential conflict of interest was reported by the authors.

References

1. Macias A, Sanchez-Montalva A, Salvador F *et al*: Epidemiology and diagnosis of pleural tuberculosis in a low incidence country with high rate of immigrant population: A retrospective study. *Int J Infect Dis.* 2019; 78:34-38.
2. Glaziou P, Floyd K, Raviglione MC: Global Epidemiology of Tuberculosis. *Semin Respir Crit Care Med.* 2018; 39(3):271-285.
3. Harding E: WHO global progress report on tuberculosis elimination. *Lancet Respir Med.* 2020; 8(1):19.
4. Saks AM, Posner R: Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. *Clin Radiol.* 1992; 46(6):387-390.
5. Zhai K, Lu Y, Shi HZ: Tuberculous pleural effusion. *J Thorac Dis.* 2016; 8(7):E486-494.
6. Wang X, Yang Z, Fu Y *et al*: Insight to the Epidemiology and Risk Factors of Extrapulmonary Tuberculosis in Tianjin, China during 2006-2011. *PLoS One.* 2014; 9(12):e112213.
7. Pang Y, An J, Shu W *et al*: Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008-2017. *Emerg Infect Dis.* 2019; 25(3):457-464.
8. Seiscento M, Vargas FS, Rujula MJ *et al*: Epidemiological aspects of pleural tuberculosis in the state of Sao Paulo, Brazil (1998-2005). *J Bras Pneumol.* 2009; 35(6):548-554.
9. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR: Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. *Clin Infect Dis.* 2009; 49(9):1350-1357.
10. Udwadia ZF, Sen T: Pleural tuberculosis: an update. *Curr Opin Pulm Med.* 2010; 16(4):399-406.
11. Villena Garrido V, Cases Viedma E, Fernandez Villar A *et al*: Recommendations of diagnosis and treatment of pleural effusion. Update. *Arch Bronconeumol.* 2014; 50(6):235-249.
12. Wang XJ, Yang Y, Wang Z *et al*: Efficacy and safety of diagnostic thoracoscopy in undiagnosed pleural effusions. *Respiration.* 2015; 90(3):251-255.
13. Steingart KR, Flores LL, Dendukuri N *et al*: Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis. *PLoS Med.* 2011; 8(8):e1001062.
14. Wong CF: Early diagnosis of tuberculous pleural effusion: apart from pleural fluid adenosine deaminase, pleural biopsy still has a role. *Hong Kong Med J.* 2018; 24(3):316-317.
15. Flores-Ibarra AA, Ochoa-Vazquez MD, Sanchez-Tec GA: [Diagnostic strategies in the Tuberculosis Clinic of the Hospital General La Raza National Medical Center]. *Rev Med Inst Mex Seguro Soc.* 2016; 54(1):122-127.
16. Klimiuk J, Krenke R, Safianowska A, Korczynski P, Chazan R: Diagnostic performance of different pleural fluid biomarkers in tuberculous pleurisy. *Adv Exp Med Biol.* 2015; 852:21-30.

17. Abrao FC, de Abreu IR, Miyake DH, Busico MA, Younes RN: Role of adenosine deaminase and the influence of age on the diagnosis of pleural tuberculosis. *Int J Tuberc Lung Dis.* 2014; 18(11):1363-1369.
18. American Thoracic S, Infectious Diseases Society of A: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005; 171(4):388-416.
19. Niederman MS, Mandell LA, Anzueto A *et al*: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med.* 2001; 163(7):1730-1754.
20. Petborom P, Dechates B, Muangnoi P: Differentiating tuberculous pleuritis from other exudative lymphocytic pleural effusions. *Ann Palliat Med.* 2020; 9(5):2508-2515.
21. Sales RK, Vargas FS, Capelozzi VL *et al*: Predictive models for diagnosis of pleural effusions secondary to tuberculosis or cancer. *Respirology.* 2009; 14(8):1128-1133.
22. Porcel JM, Vives M, Cao G *et al*: Biomarkers of infection for the differential diagnosis of pleural effusions. *Eur Respir J.* 2009; 34(6):1383-1389.
23. Zhang M, Li D, Hu ZD, Huang YL: The diagnostic utility of pleural markers for tuberculosis pleural effusion. *Ann Transl Med.* 2020; 8(9):607.
24. Luo Y, Yan F, Xue Y *et al*: Diagnostic utility of pleural fluid T-SPOT and interferon-gamma for tuberculous pleurisy: A two-center prospective cohort study in China. *Int J Infect Dis.* 2020; 99:515-521.
25. Ren Z, Hu Y, Xu L: Identifying tuberculous pleural effusion using artificial intelligence machine learning algorithms. *Respir Res.* 2019; 20(1):220.

Table 1. Clinical and laboratory findings of the 125 patients with PE

	Total(n=125)	TBPE (n=63)	Non-TBPE(n=62)	p Value
Age(years)	58.0(38.0-70.5)	42.0(29.0-65.0)	67.0(53.0-74.0)	0.000
Male	71(56.8%)	46(73.0%)	25(40.3%)	0.000
Cancer	44(35.2%)	1(1.6%)	43(69.4%)	0.000
Unilateral PE	116(92.8%)	62(98.4%)	54(87.1%)	0.017
Cough	101(80.8%)	52(82.5%)	49(79.0%)	0.656
Fever	41(32.8%)	33(52.4%)	8(12.9%)	0.000
Chest pain	50(40.0%)	30(47.6%)	20(32.3%)	0.080
Night sweats	4(3.2%)	3(4.8%)	1(1.6%)	0.619
In blood:				
ESR (mm/h)	35.0(21.5-56.0)	40.0(28.0-60.0)	30.0(12.0-45.7)	0.031
CRP (mg/L)	36.1(13.2-90.8)	76.5(30.1-131.3)	18.1(8.4-41.0)	0.000
T-SPOT	73(58.4%)	59(93.7%)	14(22.6%)	0.000
In PE:				
L%	90(77.5-96.0)	93.0(84.0-98.0)	85.0(67.7-94.0)	0.000
Protein(g/L)	64.7(53.0-79.6)	69.5(58.5-81.6)	61.7(50.4-77.5)	0.063
ADA(U/L)	26.7(8.6-41.7)	40.9(33.6-49.3)	9.5(7.1-12.9)	0.000
LDH(U/L)	306.2(216.2-571.4)	415.1(262.0-610.7)	269.4(207.7-392.9)	0.299

Note: Data in the table are expressed either as a frequency (percentage) or a median (interquartile range); PE: pleural effusion; TBPE: tuberculous pleural effusion; non-TBPE: non-tuberculous pleural effusion; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; T-SPOT: T-cell spot; L%: lymphocyte ratio; ADA: adenosine deaminase.

Table 2. Youden Index and cut-off value of continuous data

	Youden Index	cut-off value
Age (years)	0.443	46.5
ESR (mm/h)	0.23	27.5
CRP (mg/L)	0.457	52.8
L%	0.264	91.5
ADA (U/L)	0.856	24.5

Note: ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; L%: lymphocyte ratio; ADA: adenosine deaminase.

Table 3. The diagnostic performance of single indicator for TBPE

	Sensitivity	Specificity	PPV	NPV	Accuracy
Age≤46.5 years	0.556	0.887	0.833	0.663	0.720
Male	0.730	0.597	0.648	0.685	0.664
No cancer	0.984	0.694	0.765	0.977	0.840
Fever	0.524	0.871	0.805	0.643	0.696
Unilateral PE	0.984	0.129	0.534	0.889	0.560
Positive T-SPOT	0.937	0.774	0.808	0.923	0.856
ESR≥27.5 mm/h	0.762	0.468	0.593	0.659	0.616
CRP≥52.8 mg/L	0.651	0.806	0.774	0.694	0.728
L%≥91.5%	0.603	0.661	0.644	0.621	0.632
ADA≥24.5 U/L	0.937	0.919	0.922	0.934	0.928

Note: PPV: positive predictive value; NPV: negative predictive value; PE: pleural effusion; T-SPOT: T-cell spot; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; L%: lymphocyte ratio; ADA: adenosine deaminase.

Table 4. Score for diagnosis based on the B coefficient of the variables

Variable	Scoring criteria	B coefficient	Score
Age	Age \leq 46.5years	4.96	4.96
Gender	Male	2.44	2.44
Cancer	No cancer	3.19	3.19
T-SPOT	Positive T-SPOT	4.69	4.69
CRP	CRP \geq 52.8mg/L	1.84	1.84
ADA	ADA \geq 24.5U/L	2.48	2.48

Note: T-SPOT: T-cell spot; CRP: C-reactive protein; ADA: adenosine deaminase.

Table 5. The performance of scoring model

	Scoring model
cut-off value	≥ 11.038
Youden Index	0.905
Sensitivity	0.937
Specificity	0.968
Accuracy	0.992
PPV	1.000
NPV	0.939

Note: PPV: positive predictive value; NPV: negative predictive value.




Figure 1. The diagnostic value for TBPE. (A) The diagnostic value of ESR, CRP, Lymphocyte ratio and ADA for TBPE, the AUC value was 0.623, 0.760, 0.707 and 0.898 respectively; AUC: area under the curve. (B) The diagnostic value of Age for TBPE, the AUC value was 0.752.




Figure 2. The diagnostic value of Scoring model for TBPE. The AUC value was 0.992; AUC: area under the curve.